Literature DB >> 14656690

Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia.

Dariusz P Olszyna1, Annelies Verbon, John P Pribble, Terence Turner, Tim Axtelle, Sander J H van Deventer, Tom van der Poll.   

Abstract

To determine the role of CD14 in lipopolysaccharide (LPS)-induced release of chemokines, 16 humans were injected with LPS (4 ng/kg) preceded (-2 h) by intravenous IC14, an anti-human CD14 monoclonal antibody, or placebo. LPS elicited increases in interleukin (IL)-8 concentrations in plasma and in lysates of red blood cell (RBC), polymorphonuclear cell and mononuclear cell fractions, which were all reduced by IC14. LPS also induced rises in the plasma and RBC levels of monocyte chemoattractant protein (MCP)-1, which were diminished by IC14. Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, chemokines that in contrast to IL-8 and MCP-1 can not bind to the Duffy antigen receptor for chemokines on RBCs, were only detected in plasma. IC14 attenuated the LPS-induced release of MIP-1beta, but not of MIP-1alpha. IL-8 and MCP-1, but not MIP-1alpha and MIP-1b, circulate in RBC-associated form during endotoxemia. LPS-induced chemokine release is, in part, mediated by an interaction with CD14.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656690

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  4 in total

1.  CD14 Counterregulates Lipopolysacharide-Induced Tumor Necrosis Factor-α Production in a Macrophage Subset.

Authors:  Anja Grahnert; Ronald Weiss; Erik Schilling; Nancy Stanslowsky; Ulrich Sack; Sunna Hauschildt
Journal:  J Innate Immun       Date:  2019-01-17       Impact factor: 7.349

2.  CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.

Authors:  Ebbe Billmann Thorgersen; Bernt Christian Hellerud; Erik Waage Nielsen; Andreas Barratt-Due; Hilde Fure; Julie Katrine Lindstad; Anne Pharo; Erik Fosse; Tor Inge Tønnessen; Harald Thidemann Johansen; Albert Castellheim; Tom Eirik Mollnes
Journal:  FASEB J       Date:  2009-10-19       Impact factor: 5.191

3.  Directed evolution of an LBP/CD14 inhibitory peptide and its anti-endotoxin activity.

Authors:  Li Fang; Zhi Xu; Guan-song Wang; Fu-yun Ji; Chun-xia Mei; Juan Liu; Guo-ming Wu
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 4.  Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets.

Authors:  Andreas Barratt-Due; Søren Erik Pischke; Per H Nilsson; Terje Espevik; Tom Eirik Mollnes
Journal:  J Leukoc Biol       Date:  2016-08-31       Impact factor: 4.962

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.